Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis launches review into safety of eye drug Beovu

02/25/2020 | 05:37am EDT

Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.

The Swiss drugmaker's shares fell nearly 3% in early trading after the ASRS communicated to its members about the drug, a replacement for Novartis' blockbuster Lucentis.

Since Beovu's approval last October, ASRS has received reports of 14 cases of vasculitis, an inflammation of the blood vessels, of which 11 were designated occlusive retinal vasculitis - a sight-threatening inflammatory eye condition.

Novartis said it was aware of recently reported adverse effects of the drug, adding it "stands behind the safety and efficacy of Beovu."

"In addition to our own internal assessment, we have engaged an external safety review committee (SRC) to further evaluate these post-marketing cases. We will continue to share details as they become available," the company said.

Around 46,000 injections of Beovu have so far been administered, Novartis said. The U.S. Food and Drug Administration was aware of the review, while the company is now informing other health authorities.

"Our clinical development and pharmacovigilance teams are working with healthcare professionals to quickly obtain and evaluate all available information in order to classify these events and identify potential risk factors," Novartis said.

The company received approval from the FDA for Beovu in October and the go-ahead in Europe earlier this month.

Beovu injections are used to treat wet age-related macular degeneration, a condition which can eventually lead to blindness and affects around 20 million people worldwide.

(Reporting by John Revill; editing by Jason Neely, Kirsten Donovan)

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DEERE & COMPANY 2.40% 336.47 Delayed Quote.22.27%
JASON CO., LTD. -0.54% 556 End-of-day quote.-16.77%
MEMBERS CO., LTD. -2.69% 3250 End-of-day quote.40.15%
NOVARTIS AG 0.41% 86.02 Delayed Quote.2.47%
SWISS RE LTD -0.05% 85.12 Delayed Quote.2.14%
THE LEAD CO., INC. -8.47% 746 End-of-day quote.-11.19%
All news about NOVARTIS AG
06/20NOVARTISá : Gene Therapy Zolgensma Shows Efficacy in Children With Spinal Muscul..
06/18NOVARTISá : Study Shows Improved Motor Function in Children with Spinal Muscular..
06/18PRESS RELEASEá : Novartis: New Zolgensma data -3-
06/18PRESS RELEASEá : Novartis: New Zolgensma data -2-
06/18PRESS RELEASEá : Novartis: New Zolgensma data demonstrate age-appropriate develo..
06/18NOVARTISá : New Zolgensma data demonstrate age-appropriate development when used..
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
06/17NOVARTIS INDIAá : Consolidated Net Profit Climbs in Fiscal Q4
06/17CureVac may let contractors make rival vaccines if own shot fails -CEO
06/17CureVac may let contractors make rival vaccines if own shot fails - CEO
More news
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,7x
Yield 2021 3,53%
Capitalization 208 B 209 B -
EV / Sales 2021 4,48x
EV / Sales 2022 4,19x
Nbr of Employees 110 000
Free-Float 87,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 106,77 $
Last Close Price 92,83 $
Spread / Highest target 60,4%
Spread / Average Target 15,0%
Spread / Lowest Target -5,68%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.47%208 642
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
ABBVIE INC.5.57%199 795